| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/18/2008 | WO2008110695A1 Novel multimeric molecules, method for preparing same and use thereof in the preparation of drugs |
| 09/18/2008 | WO2008110578A2 Markers, antibodies and recombinant scfvs for mesenchymal stem cell-sub-populations and osteoclasts |
| 09/18/2008 | WO2008110006A1 Biomarkers of prostate cancer and uses thereof |
| 09/18/2008 | WO2008109996A1 Assessing chemotherapy resistance of colorectal tumors by determining sparc hypermethylation |
| 09/18/2008 | WO2008109976A1 Kunitz-type recombinant inhibitor |
| 09/18/2008 | WO2008109953A1 Method for treating cancer via the mucosal administration of interleukin |
| 09/18/2008 | WO2008091620A3 Combination therapy comprising romidepsin and i.a. bortezomib |
| 09/18/2008 | WO2008088524A3 Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor |
| 09/18/2008 | WO2008087419A3 Animal model for adhd |
| 09/18/2008 | WO2008086042A3 Preventing infection by a measles or respiratory syncytial virus |
| 09/18/2008 | WO2008076437A3 Activin-actrii antagonists and uses for increasing red blood cell levels |
| 09/18/2008 | WO2008076255A3 Canine thymic stromal lymphopoietin protein and uses thereof |
| 09/18/2008 | WO2008074813A3 Optiogenin for the treatment of neural diseases |
| 09/18/2008 | WO2008073631A9 Composition for cartilage |
| 09/18/2008 | WO2008063868A3 Attenuation of vasoactive oxygen carrier-induced vasoconstriction |
| 09/18/2008 | WO2008057995A3 Hcv protease inhibitors |
| 09/18/2008 | WO2008049070A3 Il-17c antagonists and methods of using the same |
| 09/18/2008 | WO2008036970A3 Insulin-degrading enzyme mutants and methods of use |
| 09/18/2008 | WO2008032073A3 Novel nematode protein and its use in producing anthelminthic agents and vaccines |
| 09/18/2008 | WO2008029276A8 Compositions and methods for the treatment of ophthalmic disease |
| 09/18/2008 | WO2008029169A3 Method of treating respiratory disorders |
| 09/18/2008 | WO2008019018A3 Bioactive molecular matrix and methods of use in the treatment of disease |
| 09/18/2008 | WO2008013589A3 Treatment of ras-expressing tumors |
| 09/18/2008 | WO2008002663A3 Immunogenic protein constructs |
| 09/18/2008 | WO2007121124A3 Hcv inhibitors comprising beta amino acids and their uses |
| 09/18/2008 | WO2007120899A3 Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof |
| 09/18/2008 | WO2007081516A3 Tumor activated prodrugs |
| 09/18/2008 | WO2006028645A3 Method for remodeling bone and related sutures |
| 09/18/2008 | US20080228005 Polymorphs of suberoylanilide hydroxamic acid |
| 09/18/2008 | US20080227963 Process for preparing glycopeptide phosphonate derivatives |
| 09/18/2008 | US20080227956 Novel morphogenic protein compositions of matter |
| 09/18/2008 | US20080227955 Nematode PAN and ZP Receptor-Like Sequences |
| 09/18/2008 | US20080227954 Therapeutic amino acid sequences for use in treatment and prevention of viral, infectious, cancerous, diabetic, incontinent, hypertensive and nervous system disorders |
| 09/18/2008 | US20080227862 histone deacetylase (HDAC) inhibitor useful in selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells; have a high bioavailability and gives high blood levels of the active compounds over a long time |
| 09/18/2008 | US20080227861 Inhibition of Allergic Contact Dermatitis By N-L-ALPHA-ASPARTYL-L-PHENYLALANINE 1-METHYL ESTER |
| 09/18/2008 | US20080227761 Ameliorating a Th1 mediated immune pathology such as multiple sclerosis by raaising the serum concentration of estrogen to 30-1000 pg/ml by administering, e.g., 17-beta-estradiol, estriol or estrone; and administering a glatiramer acetate |
| 09/18/2008 | US20080227756 Administering a bisphosphonate until the bone mineral density is within a normal range, interrupting administration to enable the development of the sectional momentum of inertia, and resuming administration when the bone mineral density falls by 5-10% of the normal range |
| 09/18/2008 | US20080227745 Methods and compositions for soluble CPG15 |
| 09/18/2008 | US20080227740 Compositions and Methods for Elimination of Unwanted Cells |
| 09/18/2008 | US20080227739 Isolated polypeptide comprising amino acid sequence encoded by polynucleotide; physiologically acceptable carriers and immunostimulants |
| 09/18/2008 | US20080227738 Compositions and methods for cell dedifferentiation and tissue regeneration |
| 09/18/2008 | US20080227734 Mutant Lrp5/6 Wnt-Signaling Receptors in Cancer Diagnosis, Prognosis, and Treatment |
| 09/18/2008 | US20080227726 High density lipoproteins comprising apolipoproteins and phospholipids; reduced cholesterol content; atherogenic vascular disease |
| 09/18/2008 | US20080227725 Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes |
| 09/18/2008 | US20080227724 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents |
| 09/18/2008 | US20080227723 Using immunogenic peptide for therapy of immunological liver damage or hepatotoxic chemical substance-induced liver damage, and Hepatitis C |
| 09/18/2008 | US20080227722 Targeted Drug Delivery of Pain and Addiction Therapies Using Opioid Receptor-Mediated Internalization |
| 09/18/2008 | US20080227721 Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders |
| 09/18/2008 | US20080227720 Tumor cytotoxicity induced by modulators of the CXCR4 receptor |
| 09/18/2008 | US20080227719 administering to a patient an effective dosage of a polypeptide comprising an N-terminal segment of A beta , the segment beginning at residue 1-3 of A beta and ending at residues 7-11 of A beta to treat disease associated with amyloid deposit of A beta in the brain Alzheimer's disease, Down's syndrome |
| 09/18/2008 | US20080227718 administering to a patient an effective dosage of a polypeptide comprising an N-terminal segment of A beta , the segment beginning at residue 1-3 of A beta and ending at residues 7-11 of A beta to treat disease associated with amyloid deposit of A beta in the brain Alzheimer's disease, Down's syndrome |
| 09/18/2008 | US20080227717 Potent compstatin analogs |
| 09/18/2008 | US20080227716 protecting the scalp from hair treatment dyes or colors capable of dyeing, tinting, deforming, hardening, conditioning, softening, repairing or styling hair using short-chain peptide prefereably containing 6-12 amino acids |
| 09/18/2008 | US20080227715 Liquid composition of factor VII polypeptides |
| 09/18/2008 | US20080227714 Human Tumor Necrosis Factor TR18 and Methods Based Thereon |
| 09/18/2008 | US20080227713 amino acid sequence of Ser1-Pro2-Lys3-Met4-Val5-Gln6-Gly7-Ser8-Gly9-Cys10-Phe11-Gly12-Arg13-Lys14-Met15-Asp16-Arg17-Ile18-Ser19-Ser20-Ser21-Ser22-Gly23-Leu24-Gly25-Cys26-Lys27-Val28-Leu29-Arg30-Lys31-His32, either Met4, Met15, or both are oxidized; diagnosis heart failure |
| 09/18/2008 | US20080227712 Polypeptide for use in treatment and prevention of leukemia, hemophilia and nervous system disorders |
| 09/18/2008 | US20080227711 Cxc-Chemokine Antagonists |
| 09/18/2008 | US20080227710 useful in the treatment of hepatocellular carcinomas (HCCs) which do not express the asialoglycoprotein receptor (ASGP-R) and avoids the need of a tumor biopsy |
| 09/18/2008 | US20080227709 Gene expression in peripheral blood mononuclear cells from children with diabetes |
| 09/18/2008 | US20080227708 introducing an effective amount of insulin growth factor binding protein-3 (IGFBP-3) into prostate cancer cells to promote apoptosis and inhibit cellular proliferation |
| 09/18/2008 | US20080227707 Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20 |
| 09/18/2008 | US20080227706 Polypeptides and polynucleotides; genetic engineering; medical diagnosis; treatment of infection causes sepsis, meningitis, pneumonia, cellulitis, osteomyelitis, septic arthritis, endocarditis or epiglottis; bacterial protein antigen vaccine |
| 09/18/2008 | US20080227705 Apoptosis-inducing agent and method for inducing apoptosis |
| 09/18/2008 | US20080227704 CXCL13 binding proteins |
| 09/18/2008 | US20080227703 neublastin neurotrophic factor polypeptides for treating neuropathy |
| 09/18/2008 | US20080227702 Providing an osteogenic protein in a biocompatible bioresorbable carrier to defect locus, thereby inducing formation of functional replacement cartilage tissue; medical device for repairing a defect in an intervertebral disc |
| 09/18/2008 | US20080227701 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 09/18/2008 | US20080227700 contacting the protein with a polypeptide up to about 50 amino acids in length having molecular chaperone activity; protein conformation disease is Alexander's disease, Alzheimer's disease, Creutzfeld-Jakob disease, Parkinson's disease, Huntington's disease, cataract, retinitis pigmentosa, prion disease |
| 09/18/2008 | US20080227699 Therapeutic Agent for Neurodegenerative Diseases |
| 09/18/2008 | US20080227698 oligopeptide antagonizes binding of DKK1 to LRP5 when in contact with LRP5; degenerative bone diseases |
| 09/18/2008 | US20080227697 Bacterial protein phosphoinositide probes and effectors |
| 09/18/2008 | US20080227696 an analog of a hormone, a cytokine, a lymphokine, a chemokine or an interleukin, and may bind to any heparin binding growth factor receptor; soluble drugs and as coatings for medical devices; homodimeric sequences branched from a single amino acid residue |
| 09/18/2008 | US20080227695 reduced expression and/or function of Dlg (discs large) is an important factor for tumor formation; measuring the expression and/or function of Dlg |
| 09/18/2008 | US20080227694 Protein composed of sequence number 1 or 2; proteasome and polyubiquitin chain inhibitors; interaction with ZNF216 and/or AWP1 |
| 09/18/2008 | US20080227693 Improved flowability and solubility with less dust and static compared to lyophilization; acid addition salt powders; ambient storage stability |
| 09/18/2008 | US20080227692 Containing angiopoietin 1 and/or Fibulin 5; diabetic retinopathy, age related macular degeneration; inducing angiogenesis, enhancing endothelial cell survival, preventing vascular leakage |
| 09/18/2008 | US20080227691 Blood Coagulation FVIII Analogues |
| 09/18/2008 | US20080227690 Particles for inhalation having rapid release properties |
| 09/18/2008 | US20080227689 Autoimmune disorders; polypeptide GalNAc transferase 1 (ppGalNAcT-1) suppression; antisense RNA |
| 09/18/2008 | US20080227688 Inhibition of viral replication |
| 09/18/2008 | US20080227687 Photodynamic therapy; such as annexin V protein complexes selectively binding to tumor vasculature endothelial cells; delivery via bloodstream; simultaneously treating metastatic cancer; protecting normal cells |
| 09/18/2008 | US20080227686 Novel Peptides that Promote Lipid Efflux |
| 09/18/2008 | US20080227685 Polypeptide comprising the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO:125); activating guanylate cyclase C (GC-C) receptor; gastroesophageal reflux disease, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, dyspepsia, constipation |
| 09/18/2008 | US20080227684 Small Molecule Inhibitors of PDZ Interactions |
| 09/18/2008 | US20080227683 Compounds Having Antitumor Activity |
| 09/18/2008 | US20080227200 Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and DNA coding for the same |
| 09/18/2008 | US20080227160 Using vector transformation to generate transgenic cells expressing interfering RNA sequences; treatment and prevention of metabolic disorders |
| 09/18/2008 | US20080227158 Novel polypeptide, novel dna and novel antibody |
| 09/18/2008 | US20080227157 Nucleic acids encoding fusion proteins based on ribosome-inactivating proteins of the mistletoe Viscum Album |
| 09/18/2008 | US20080227156 Nucleotide sequences coding myostatin epitopes for use in treatment and prevention of diabetic disorders; immunotherapy |
| 09/18/2008 | US20080227155 Pegylated soluble gp130-dimers useful as a medicament |
| 09/18/2008 | US20080227152 In vivo incorporation of unnatural amino acids |
| 09/18/2008 | US20080227149 Interferon-Alpha Polypeptides and Conjugates |
| 09/18/2008 | US20080227147 Lysosomal enzyme for use in destroying clostridial bacteria in chesse and milk products; improving food processing |
| 09/18/2008 | US20080227138 Identifying sclerostin antagonist via abilty to prevent apoptosis; treating osteoporosis |
| 09/18/2008 | US20080227135 Autoimmune Conditions and NADPH Oxidase Defects |
| 09/18/2008 | US20080227127 Human NK3-Related Prostate Specific Gene-1 |
| 09/18/2008 | US20080227121 Using collagen XIII peptide as evaluative tool in identifying modulators monocyte efflux into interstitial space; treating chronic inflammatory disorders |
| 09/18/2008 | US20080227110 Expression vector comprising nucleotide sequences coding human polypeptide for use in treatment of metabolic disorders; immunotherapy |